A new regimen for heparin use in acute coronary syndromes

American Heart Journal

Volumn 138, Issue 2 I, 1999, Pages 313-318

  Hochman, J S ^a   Wali, A U ^a   Gavrila, D ^a   Sim, M J ^a   Malhotra, S ^a   Palazzo, A M ^a   De La Fuente, B ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN;

ADULT; AGED; ANGINA PECTORIS; ANTICOAGULANT THERAPY; ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; FEMALE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0032800304     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70118-3     Document Type: Article

References (25)

1. Granger CB, Hirsh J, Califf RM, Col J, White HD, Betriu A, et al. for the (GUSTO) I trial investigators. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-1 trial. Circulation 1996;93:870-8.
2. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for ACS. Circulation 1994;90:1631-7.
3. Antman EM for the TIMI 9A Investigators. Hirudin in acute myocardial infarction safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A trial. Circulation 1994;90:1624-30.
4. Wali A, Hochman JS, Berkowitz S, Clark KA, Malhotra S, Califf RM, et al. Failure to achieve optimal anticoagulation with commonly used heparin regimens: a review of GUSTO II [abstract]. J Am Coll Cardiol 1998;31(suppl A):79A.
5. Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management. Clinical practice guideline no. 10. AHCPR publication no. 94-0602. Rockville (MD): Agency for Health Care Policy and Research; 1994.
6. Theroux P, Ouimet H, McCans J, et al. Aspirin, heparin or both to treat unstable angina. N Engl J Med 1988;319:1105-11.
7. The RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990;336:827-30.
8. Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
9. Raschke RA, Reilly BM, Guidry JR, Fontana JR, Srinivas S. The weight-based heparin dosing nomogram compared with a "standard care" nomogram: a randomized controlled trial. Ann Intern Med 1993;119:874-81.
10. Kashtan J, Conti S, Blaisdell FW. Heparin therapy for deep venous thrombosis. Am J Surg 1980;140:836-40.
11. Hassan WM, Flaker GC, Feutz C, Petroski GF, Smith D. Improved anticoagulation with a weight-adjusted heparin nomogram in patients with ACS: a randomized trial. J Thrombosis and Thrombolysis 1995;2:245-9.
12. Cipolle RJ, Rodvold KA. Heparin. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. Spokane (WA): Applied Therapeutics; 1986. p. 908-42.
13. Becker RC, Cannon CP, Tracy RP, Thompson B, Bovill EG, Desvigne-Nickens P, et al for the Thrombolysis in Myocardial Ischemia IIIB Investigators. Relation between systemic anticoagulation as determined by activated partial thromboplastin time and heparin measurements and in-hospital clinical events in unstable angina and non-Q-wave myocardial infarction. Am Heart J 1996;131:421-33.
14. Ryan TJ, Anderson JL, Antman EM, Braniff BA, Brooks NH, Califf RM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28:1328-428.
15. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1992;102(Suppl):408S-25S.
16. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, et al. Optimal therapeutic level of heparin therapy in patients with venous thromboembolism. Arch Intern Med 1992;152:1589-95.
17. Hirsh J. Heparin. N Engl J Med 1991;3324:15655-74.
18. Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, et al for the ESSENCE Group. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery diseases. N Engl J Med 1997;337:447-52.
19. White RH, Zhou H, Woo L, Mungall D. Effect of weight, sex, age clinical diagnosis and thromboplastin reagent on steady-state intravenous heparin requirements. Arch Intern Med 1997;157:2468-72.
20. Hirsh J, Van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WL. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976;53:691-5.
21. Chiu HM, Van Aken WG, Hirsh J, Regoeczi E, Horner AA. Increased heparin clearance in experimental pulmonary embolism. J Lab Clin Med 1977;90:204-15.
22. Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-9.
23. Hull RD, Raskob GE, Rosenbloom D, Panju AA, Brill-Edwards P, Ginsberg JS, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-4.
24. Baker BA, Adelman MD, Smith PA, Osborn JC. Inability of the activated partial thromboplastin time to predict heparin levels. Time to reassess guidelines for heparin assays. Arch Intern Med 1997;157:2475-9.
25. Berkowitz SD, Granger CB, Pieper KS, Lee KL, Gore JM, Simoons M, et al. Incidence and predictors of bleeding after contemporary thrombolytic therapy for myocardial infarction. The Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries (GUSTO) I Investigators. Circulation 1997;95:2508-16.